Results 11 to 20 of about 76,477,355 (241)

When IL-17 inhibitors fail : real-life evidence to switch from secukinumab to adalimumab or ustekinumab [PDF]

Dermatol Ther, 2018
Psoriasis is a chronic, systemic inflammatory disease that in the moderate to severe forms may benefit of biologics, namely TNF and IL-12/23 and IL-17 inhibitors.
de Vita, Valerio, Malagoli, Piergiorgio, Costanzo, Antonio, Conic, Rosalynn R. Z., Bragazzi, Nicola L., Damiani, Giovanni, Pacifico, Alessia, Regazzini, Roberto, Pigatto, Paolo D. M.   +8 more
core   +2 more sources

Alopecia Diffusa while Using Interleukin-17 Inhibitors against Psoriasis Vulgaris [PDF]

Case Reports in Dermatology, 2019
We report two cases of alopecia diffusa during the treatment of psoriasis vulgaris with interleukin (IL)-17 inhibitors. Psoriasis is one of the most common immune-mediated chronic skin diseases, strongly associated with IL-17A. Clinically, the monoclonal
Makiko Yajima, Tomoko Akeda, Makoto Kondo, Koji Habe, Keiichi Yamanaka   +4 more
doaj   +2 more sources

Risk of candidiasis associated with interleukin-17 inhibitors: Implications and management

Mycology
The application of interleukin-17 (IL-17) inhibitors, including secukinumab, ixekizumab, brodalumab, and bimekizumab, are associated with elevated risk of candidiasis. These medications interfere with the IL-17 pathway, which is essential for maintaining
Hazrat Bilal, Muhammad Nadeem Khan, Sabir Khan, Wenjie Fang, Wenqiang Chang, Bin Yin, Ning-Jing Song, Zhongrong Liu, Dongxing Zhang, Fen Yao, Xun Wang, Qian Wang, Lin Cai, Bing Hou, Jiayue Wang, Chunyan Mao, Lingxi Liu, Yuebin Zeng   +17 more
doaj   +2 more sources

Tofacitinib for the Treatment of Psoriasiform Dermatitis Caused by IL-17 Inhibitors: A Case Report [PDF]

J Inflamm Res, 2023
Nan Luo, Lingyuan Zhong, Nana Luo, Qiuyue Wang, Tianhao Li, Pingsheng Hao Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of ChinaCorrespondence: Pingsheng Hao; Tianhao Li, Department ...
Luo N, Hao P, Wang Q, Li T, Zhong L
core   +2 more sources

Novel Pharmacological Approaches for Inflammatory Bowel Disease: Targeting Key Intracellular Pathways and the IL-23/IL-17 Axis [PDF]

International Journal of Inflammation, 2012
This review identifies possible pharmacological targets for inflammatory bowel disease (IBD) within the IL-23/IL-17 axis. Specifically, there are several targets within the IL-23/IL-17 pathways for potential pharmacological intervention with antibodies ...
Leo R. Fitzpatrick
doaj   +2 more sources

Comparative Effects of IL-17 and IL-23 Inhibitors on Lipid Profiles and Lipid-Derived Atherogenic Indices in Patients with Psoriasis [PDF]

Pharmaceuticals
Background: Psoriasis is associated with increased cardiovascular risk and altered lipid metabolism. The comparative effects of IL-17 and IL-23 inhibitors on lipid-derived atherogenic indices remain unclear. Objective: To compare the effects of IL-17 and
Candan Celik, Mehmet Semih Çelik, Nagehan Cepik   +2 more
doaj   +2 more sources

Potential association between IL-12/23, IL-23, and IL-17 inhibitors and skin cancer: a pharmacovigilance study based on the FAERS database [PDF]

Frontiers in Pharmacology
BackgroundInterleukin (IL)-12/23, IL-23, and IL-17 inhibitors are increasingly used for immune-mediated inflammatory diseases, yet their long-term risk of skin cancer remains unclear due to limited evidence from randomized controlled trials.MethodsWe ...
Xing Jiang, Yunbei Huang, Yunbei Huang, Min Xie, Min Xie, Li Peng, Li Peng, Mengyao Xu, Zhongyu Qi, Guojun Wang, Xiaofeng Pu   +10 more
doaj   +2 more sources

Cutaneous Adverse Reactions to IL-17 and IL-23 Inhibitors: A Clinical Review of Reaction Patterns [PDF]

Dermatol Pract Concept
Introduction: IL-17 and IL-23 inhibitors have transformed the management of moderate-to-severe psoriasis and other inflammatory diseases through targeted immune modulation.
Ali Bayrouti, Duncan MacIntyre, Vivian Le, Ingyun Park, Khoa Nguyen, Bayrouti, Ali, Nguyen, Khoa, MacIntyre, Duncan, Le, Vivian, Park, Ingyun   +9 more
core   +2 more sources

MASLD and liver fibrosis in patients with psoriasis receiving IL-17 or IL-23 inhibitors: a systematic review [PDF]

Therapeutic Advances in Gastroenterology
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is more prevalent in patients with psoriasis compared to healthy individuals.
José González Fernández, Lucía Prieto-Torres, Mariano Ara Martín, Samuel J. Martínez-Domínguez   +3 more
doaj   +2 more sources

Treatment Persistence of Interleukin-17 Inhibitors and Factors Associated with Persistence in Patients with Psoriasis Vulgaris in Japan: Retrospective Database Study [PDF]

Dermatology and Therapy
Introduction Psoriasis vulgaris (PsV) is a chronic, immune-mediated skin disorder that significantly impairs quality of life and often necessitates long-term systemic therapy, especially in moderate-to-severe cases.
Yayoi Tada, Hideaki Kagitani, Shuichi Kimura, Naoto Tsujimoto, Kiyotaka Mochizuki   +4 more
doaj   +2 more sources